Comment from Lee Hasselbacher

Summary: The Reproductive Health Outcomes and Disparities (RHOADs) Research Lab at the University of Chicago submitted this comment in support of the citizen petitions. They argue that the FDA should remove the mifepristone REMS or refrain from further restricting access, citing research that shows such regulations create significant barriers to care and lead to adverse maternal, infant, and socio-economic outcomes.